Inovio Pharmaceuticals, Inc.
INO
$1.68
$0.053.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | 13.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | 13.92% |
| Cost of Revenue | -20.37% | -28.83% | -37.11% | -23.06% | -25.32% |
| Gross Profit | 19.64% | 28.83% | 36.84% | 23.37% | 25.55% |
| SG&A Expenses | -5.07% | -8.55% | -16.10% | -14.63% | 37.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.69% | -22.44% | -30.67% | -20.23% | -10.13% |
| Operating Income | 14.20% | 22.44% | 30.46% | 20.44% | 10.24% |
| Income Before Tax | 119.43% | -80.79% | 27.04% | 35.36% | 22.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 119.43% | -80.79% | 27.04% | 35.36% | 22.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.43% | -80.79% | 27.04% | 35.36% | 22.48% |
| EBIT | 14.20% | 22.44% | 30.46% | 20.44% | 10.24% |
| EBITDA | 14.11% | 22.53% | 30.51% | 20.54% | 9.81% |
| EPS Basic | 109.39% | 2.48% | 48.90% | 61.02% | 41.24% |
| Normalized Basic EPS | 109.53% | 5.23% | 48.75% | 60.49% | 32.32% |
| EPS Diluted | 109.39% | 2.48% | 48.90% | 61.02% | 41.24% |
| Normalized Diluted EPS | 109.53% | 5.23% | 48.75% | 60.49% | 32.32% |
| Average Basic Shares Outstanding | 106.82% | 85.39% | 42.77% | 65.78% | 31.93% |
| Average Diluted Shares Outstanding | 106.82% | 85.39% | 42.77% | 65.78% | 31.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |